By contrast, KRAS/CCL2/IL1B expression did not impact the survival of patients with squamous cell lung carcinoma (a tumor with low KRAS mutation frequency) (Figure 7c, upper right). This evidence concerns the gene KRAS and squamous cell lung carcinoma.